David Moadel

David Moadel

InvestorPlace Contributor

Expertise: Stocks, Options, Precious metals, Bitcoin, Altcoins

Education: Master's degree in education from the American College of Education, Bachelor's degree in education from Florida Atlantic University, Associate's degree in liberal arts from Palm Beach Community College

About David:
David Moadel is a financial writer for InvestorPlace.com. He has a master’s degree in education and has authored financial content for multiple websites.

David is also active as a social media influencer, with tens of thousands of followers on YouTube, Twitter, StockTwits, and other popular sites. David writes on topics ranging from stocks to cryptocurrencies, options, precious metals, bonds, futures, and other areas of finance.

Focusing on data rather than emotions, David is always on the lookout for new pathways to financial freedom. Count on David for wealth-building strategies and resources for investors and traders of all financial backgrounds.

You can follow David on YouTube, Twitter, StockTwits and LinkedIn.

Recent Articles

Put a Lid on It! Tupperware Stock Is NOT a Meme Stock to Own Now.

By David Moadel, InvestorPlace Contributor

Don't try to be cute or clever with Tupperware stock as the financial facts don't bode well for Tupperware Brands.

Powerschool Stock’s Buyout Bait: Don’t Get Hooked on a Risky Rumor

By David Moadel, InvestorPlace Contributor

Keep your Powerschool stock position size very small, even if you expect Powerschool Holdings to get bought out soon.

Luminar Stock Analysis: The Low-Cost Ticket to the Self-Driving Revolution

By David Moadel, InvestorPlace Contributor

Luminar Technologies stock has crashed but could rebound rapidly as Luminar Technologies demonstrates improving bottom-line financials.

‘U’ Is for Uranium: Power Up Your Portfolio With Energy Fuels Stock

By David Moadel, InvestorPlace Contributor

Energy Fuels stock offers prime exposure to uranium and more as Energy Fuels stays highly active and financially stable.

No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.

By David Moadel, InvestorPlace Contributor

It's time to take CytomX Therapeutics stock seriously as CytomX Therapeutics forges a crucial partnership with a pharmaceutical powerhouse.

Load More